Anemia Treatment and Its Clinical Implications in Patients Receiving Hemodialysis Hyporesponsive to Erythropoietin-Stimulating Agents
The ESA hyporesponder subpopulation had a high burden of red blood cell transfusion use, clinical events, and health care resource utilization.
Authors
- Sally Wetten
- James B. Wetmore (ORCID: https://orcid.org/0000-0003-1380-8597)
- Guo Haifeng
- Liyuan Ma
- George Mu
- Gema Requena
- Suying Li
- David T. Gilbertson
- Julie Rouette
- Anna Richards
- Jiannong Liu
Institutions
- GlaxoSmithKline (United States) (US)
- GlaxoSmithKline (Canada) (CA)
- Hennepin Healthcare Research Institute (US)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1016/j.xkme.2026.101269
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00